IN8bio (NASDAQ:INAB) Stock, Quote.Headers.trade-ideas

IN8BIO INC

IN8bio

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Wall-Street-ai7-1

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ENSC

GNPX

ALPS ETF Trusthen & Steers Global Realty Majors ETF

INAB

JCSE

SGMO

Dow Falls Over 150 Points; General Motors Tops Q3 Views

Apple, Nio, CVS Health, Stellantis, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Pre-Market Outlook

Movers

ADXN

ATNI

BIVI

BOOM

IRTC

KSCP

MEDP

MKTW

NTBL

SNSE

TCBP

Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

movers image

ALTM

AMBO

CTCX

ICCT

LDTC

MLEC

NMHI

OTRK

PALT

PLBY

RMCO

TIGR

Why Saratoga Investment Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

IN8bio Inc

INABA DENKISANGYO CO LTD by Inaba Denkisangyo Co., Ltd.

Inaba Denkisangyo Co Ltd

INABA SEISAKUSHO CO LTD by INABA SEISAKUSHO CO LTD.

Inaba Seisakusho Co Ltd

Inabata & Co Ltd

Press Releases

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

General

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases

Earnings

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

Health Care

IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025

IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025

IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

Analyst Ratings

IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025

Abpro Hldgs

Aprea Therapeutics

BioCardia

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Equillium

Evaxion

HCW Biologics

iBio

Immuron Limited - American Depositary Shares

Immuron

Kairos Pharma

Moleculin Biotech

Marker Therapeutics

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NextCure

BiomX

Portage Biotech

Synlogic

XTL Biopharmaceuticals Ltd. - American Depositary Shares

XTL Biopharmaceuticals

HC Wainwright & Co.

Jones Trading

Laidlaw & Co.

JonesTrading

EF Hutton

Comments

IN8bio

IN8bio (NASDAQ:INAB) Stock, Quote.Headers.trade-ideas

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell